Clinical Trial: Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

In this podcastBrian Rini, M.D., a member of the Kidney Cancer Association's Professional Group, discusses a new treatment for renal cancer that is being tested in a clinical trial.  For details of this trial pleaseclick here or
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center elaborates on the preferred agents on the 2nd line setting of renal cell carcinoma if a patient progresses on pembrolizumab/axitinib... Author: obr Added: 06/26/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares on how to decide between combinations of immuno-oncology (I-O) and TKIs for treating 1st line renal cell carcinoma (RCC). Author: obr Added: 06/26/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Conclusion: We defined four cc RCC groups depending on G, CLIC1 expression and pattern: i) G3/NM/low CLIC1+, ii) G2/CM/mild CLIC1+ iii) G1 or G2/NM or CM /high CLIC1+, and iv) G2/M /high CLIC1+.
Source: Cancer Genomics and Proteomics - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect. Oncol Rep. 2019 Jun 20;: Authors: Xu HY, Li N, Yao N, Xu XF, Wang HX, Liu XY, Zhang Y Abstract A satisfactory cure rate for renal cell carcinoma (RCC) is difficult to achieve through traditional immunotherapy. RCC has a relatively high spontaneous regression rate due to tumor immune escape. However, tumor‑derived exosomes (TEXs), which effectively carry tumor‑associ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Targeted therapies were associated with"modest survival advantages" in elderly Medicare patients with metastatic renal cell carcinoma (mRCC) in a retrospective study.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
This review focuses on what is the biological basis of esophageal cancer for immunotherapy, how to screen out the patients who can benefit from immunotherapy, and whether the toxic side effects of immunotherapy are manageable. AbstractConsidering the benefits of immunotherapy in advanced melanoma, non –small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the applicatio n of immunotherapy suc...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
We describe common side effects of this treatment, and advise how they are best prevented and managed.
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionRF ablation, cryoablation, and MW ablation are equivalent at 2 years for treatment of T1a RCC for therapeutic outcome, stability of renal function, and low adverse event rate.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
FRIDAY, June 21, 2019 -- Prospective validation of existing renal cell carcinoma (RCC) prediction models demonstrates a decrease in their predictive ability, according to a study published online June 19 in the Journal of Clinical Oncology. Andres...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Kidney Cancer | Podcasts | Renal Cell Carcinoma | Urology & Nephrology